CSA Medical

Executive Summary

CSA Medical is a private medical device company developing the RejuvenAir System, a novel bronchoscopic cryotherapy device for treating Chronic Bronchitis, a major subset of COPD. The system delivers a metered spray of liquid nitrogen to ablate diseased airway epithelium, promoting regeneration of healthy tissue. The company is currently evaluating the device in the pivotal SPRAY-CB clinical trial, which aims to demonstrate safety and efficacy. If successful, RejuvenAir could become the first approved therapy targeting the underlying pathophysiology of Chronic Bronchitis, addressing a significant unmet need in respiratory medicine. The company has been privately funded and is nearing a potential inflection point with trial data readouts and regulatory interactions. CSA Medical's technology has the potential to disrupt the COPD treatment landscape, which currently relies primarily on symptomatic management. Given the high prevalence of Chronic Bronchitis and the lack of disease-modifying therapies, the RejuvenAir System represents a promising innovation with substantial commercial potential pending clinical and regulatory milestones.

Upcoming Catalysts (preview)

• Q4 2026SPRAY-CB Pivotal Trial Topline Results70% success
• Q2 2027FDA Breakthrough Device Designation or Submission60% success
• TBDStrategic Partnership or Acquisition Interest50% success